Physician profile
Paul E Shepard
NPI 1467440131
$5,867.37
in general payments reported to CMS, 2019-2025
45 companies · $629 in 2025
The $629 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $379 · 2020: $505 · 2021: $919 · 2022: $701 · 2023: $1,555 · 2024: $1,178 · 2025: $629.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,363.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,363.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,528.40 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $623.84 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $402.37 | 2019-2025 | Jardiance |
| Pfizer INC. | $289.39 | 2020-2025 | |
| Astrazeneca Pharmaceuticals Lp | $267.13 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $262.14 | 2020-2024 | Mounjaro, Jardiance, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $207.69 | 2020-2024 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $194.44 | 2020-2025 | Trintellix |
| Inspire Medical Systems, INC. | $168.26 | 2023-2025 | Inspire |
| Exact Sciences Corporation | $157.91 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $135.39 | 2022-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $130.77 | 2022-2024 | |
| Abbott Laboratories | $126.10 | 2023-2024 | Freestyle Libre 3, Proclaim |
| Corium, LLC | $121.92 | 2022-2024 | Azstarys |
| Ethicon US, LLC | $120.12 | 2021 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $110.75 | 2025 | Voquezna |
| Amarin Pharma, INC. | $107.52 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $83.91 | 2022 | |
| Vivus LLC | $83.83 | 2020-2021 | |
| Astellas Pharma US INC | $82.95 | 2023-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $66.72 | 2019-2022 | |
| Allergan, INC. | $59.19 | 2020 | |
| Merck Sharp & Dohme LLC | $54.88 | 2019-2023 | Belsomra |
| Amgen INC. | $45.21 | 2023-2024 | Otezla, Repatha |
| Biohaven Pharmaceuticals, INC. | $35.70 | 2021 | |
| Antares Pharma, INC. | $34.47 | 2023 | Tlando, Nocdurna, Xyosted |
| Edwards Lifesciences Corporation | $33.66 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Sanofi-Aventis U.S. LLC | $30.77 | 2022-2024 | |
| Idorsia Pharmaceuticals US INC | $27.60 | 2023 | Quviviq |
| Genentech USA, INC. | $24.90 | 2019 | |
| Recor Medical INC | $24.55 | 2024 | Paradise Renal Denervation System |
| Medtronic, INC. | $23.24 | 2023 | Closurefast |
| Dynavax Technologies Corporation | $21.22 | 2024 | Heplisav-B |
| Otsuka America Pharmaceutical, INC. | $20.77 | 2022 | |
| Halozyme INC | $16.93 | 2023 | |
| Dermira, INC. | $16.79 | 2020 | |
| Cranial Technologies, INC | $16.74 | 2023 | Doc Band |
| Supernus Pharmaceuticals, INC. | $15.14 | 2023 | Tlando, Xyosted, Qelbree |
| Sanofi Pasteur INC. | $14.92 | 2023 | |
| Dexcom, INC. | $14.72 | 2023 | Dexcom G6 Transmitter |
| Sunovion Pharmaceuticals INC. | $14.17 | 2021 | |
| Medtronic Vascular, INC. | $13.92 | 2019 | |
| Nestle Healthcare Nutrition INC. | $13.53 | 2023 | |
| Avanir Pharmaceuticals, INC. | $11.52 | 2019 | |
| Currax Pharmaceuticals LLC | $11.28 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Shepard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.